STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Stoke Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$24.82+0.65 (+2.69%)
Close on Oct 19, 2026
- Market cap
- $1.64B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
77M of 65M shares
Institutional holders
198
31 new, 28 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
0 buys · 81 sales
Net sold $8.89M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Montrago Trustees Limited | 6,906,181 | 13.00% | 13D (active) amendment | Dec 23, 2024 |
| RTW Investments, LP | 5,940,866 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| FMR LLC | 5,600,920 | 9.80% | 13G (passive) amendment | Dec 31, 2025 |
| Abigail P. Johnson | 5,313,100 | 8.50% | 13G (passive) amendment | Jun 30, 2026 |
| Lynx1 Capital Management LP | 4,763,673 | 8.10% | 13G (passive) amendment | Mar 31, 2026 |
| Jeremy C. Green | 4,375,931 | 8.00% | 13G (passive) amendment | Jun 30, 2025 |
| Redmile Group, LLC | 4,164,120 | 6.70% | 13G (passive) amendment | Mar 31, 2026 |
| Weston Nichols | 4,038,404 | 6.50% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 3,732,540 | 6.80% | 13G (passive) amendment | Sep 30, 2025 |
| Lampert Mark N | 3,608,968 | 5.60% | 13G (passive) | Sep 23, 2026 |
| Morgan Stanley | 3,426,739 | 6.50% | 13G (passive) amendment | Dec 31, 2024 |
| Felix J. Baker | 3,336,697 | 5.80% | 13G (passive) amendment | Dec 31, 2025 |
| Wellington Group Holdings LLP | 3,095,700 | 5.20% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of STOK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,877,357 | 9.11% | $192.31M | +491,643 | 0.00% |
| Rtw Investments, LP | 5,623,525 | 8.72% | $184.00M | – | 1.57% |
| FMR LLC | 5,313,100 | 8.23% | $173.84M | −70,566 | 0.01% |
| Lynx1 Capital Management LP | 4,038,404 | 6.26% | $132.14M | −725,269 | 15.27% |
| Redmile Group, LLC | 3,945,920 | 6.12% | $129.11M | −218,200 | 8.67% |
| Wellington Management Group Llp | 3,519,301 | 5.45% | $115.15M | +423,601 | 0.02% |
| Morgan Stanley | 3,452,795 | 5.35% | $112.98M | +29,515 | 0.01% |
| Baker Bros. Advisors LP | 3,336,697 | 5.17% | $109.18M | – | 0.55% |
| Toronto Dominion Bank | 3,173,258 | 4.92% | $103.83M | – | 0.12% |
| State Street Corp | 2,852,240 | 4.42% | $93.33M | +575,728 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 2,661,739 | 4.13% | $87.09K | +727,568 | 0.01% |
| Vanguard Capital Management LLC | 2,586,937 | 4.01% | $84.64M | +231,334 | 0.00% |
| Bvf Inc/Il | 2,547,557 | 3.95% | $83.36M | – | 2.13% |
| T. Rowe Price Investment Management, Inc. | 2,415,139 | 3.74% | $79.02K | +2,164,226 | 0.05% |
| Assenagon Asset Management S.A. | 2,256,776 | 3.50% | $73.84M | +1,349,761 | 0.05% |
| Siren, L.L.C. | 1,995,347 | 3.09% | $65.29M | – | 1.32% |
| Deerfield Management Company, L.P. (Series C) | 1,823,500 | 2.83% | $59.66M | – | 0.62% |
| Jupiter Topco LLC | 1,814,408 | 2.81% | $59.36M | New | 0.02% |
| Geode Capital Management, LLC | 1,524,309 | 2.36% | $49.88M | +202,049 | 0.00% |
| Dimensional Fund Advisors LP | 1,013,911 | 1.57% | $33.17M | +23,975 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 198 | 77M | 100.0% | 31 / 77 | 57 / 28 | 11M | 4M |
| Q1 2026 | 198 | 71M | 100.0% | 44 / 80 | 52 / 27 | 12M | 5M |
| Q4 2025 | 183 | 67M | 100.0% | 46 / 54 | 58 / 13 | 8M | 7M |
| Q3 2025 | 151 | 68M | 100.0% | 38 / 47 | 41 / 20 | 8M | 6M |
| Q2 2025 | 133 | 66M | 100.0% | 23 / 51 | 33 / 16 | 9M | 7M |
| Q1 2025 | 126 | 63M | 98.2% | 24 / 44 | 31 / 27 | 8M | 3M |
| Q4 2024 | 130 | 58M | 90.3% | 29 / 39 | 42 / 16 | 9M | 9M |
| Q3 2024 | 118 | 59M | 90.8% | 24 / 38 | 36 / 20 | 10M | 9M |
| Q2 2024 | 115 | 63M | 97.0% | 34 / 48 | 22 / 22 | 15M | 15M |
| Q1 2024 | 103 | 63M | 96.9% | 32 / 36 | 26 / 9 | 16M | 2M |
| Q4 2023 | 81 | 49M | 75.4% | 7 / 28 | 30 / 21 | 8M | 3M |
| Q3 2023 | 96 | 44M | 68.1% | 17 / 26 | 36 / 20 | 3M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of STOK | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 2,260,550 | 3.50% | $65.24M | 0.17% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,884,647 | 2.92% | $61.67M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,573,585 | 2.44% | $51.49M | 0.48% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,413,700 | 2.19% | $46.26M | 0.06% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,293,694 | 2.00% | $39.99M | 0.76% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 729,201 | 1.13% | $23.86M | 0.16% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 643,537 | 1.00% | $21.06M | 0.02% | Jun 30, 2026 |
| Select Health Care Portfolio | 628,000 | 0.97% | $19.41M | 0.34% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 602,340 | 0.93% | $17.38M | 0.05% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 520,825 | 0.81% | $15.03M | 0.17% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 508,416 | 0.79% | $16.64M | 0.11% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 495,887 | 0.77% | $16.23M | 0.17% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 473,152 | 0.73% | $14.63M | 0.25% | May 29, 2026 |
| Fidelity Stock Selector Small Cap Fund | 435,300 | 0.67% | $12.56M | 0.17% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 418,934 | 0.65% | $13.71M | 0.11% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ian F. Smith | Chief Executive Officer, Director | – | – | Feb 19, 2026 |
| Barry Ticho | CHIEF MEDICAL OFFICER | 21,710 | 0.03% | Sep 3, 2026 |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | 21,370 | 0.03% | Aug 18, 2026 |
| Thomas McCauley | Chief Scientific Officer | – | – | Jul 17, 2026 |
| Jason Hoitt | Chief Patient Officer | 10,276 | 0.02% | Mar 19, 2026 |
| Thomas Leggett | Chief Financial Officer | 10,381 | 0.02% | Mar 19, 2026 |
| Alexander Cumbo | Director | – | – | Sep 25, 2026 |
| Edward M. Kaye MD | Director | 125,194 | 0.19% | Aug 18, 2026 |
| Seth Loring Harrison | Director | 17,161,713 | 26.60% | Jul 17, 2026 |
| Arthur Tzianabos | Director | 35,694 | 0.06% | Jun 5, 2026 |
| Julie Smith | Director | 0 | – | Jun 5, 2026 |
| Jennifer Burstein | Director | 0 | – | Jun 5, 2026 |
| Adrian R. Krainer | Director | 283,302 | 0.44% | Jun 5, 2026 |
| Arthur A. Levin | Director | 22,216 | 0.03% | Jun 5, 2026 |
| Clare Kahn | Director | – | – | Apr 7, 2026 |
| Garry E. Menzel | Director | 0 | – | Jun 4, 2025 |
| Trustees Ltd Montrago | 10% owner | 14,443,681 | 22.38% | Jun 6, 2025 |
| Horizon Enterprise Ltd Blue | 10% owner | 6,906,181 | 10.70% | Jun 6, 2025 |
| International Ltd Ezbon | 10% owner | – | – | Jun 6, 2025 |
| Trust Skorpios | 10% owner | 3,906,181 | 6.05% | Jun 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Barry Ticho CHIEF MEDICAL OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −3,945 | $30.51 | $120.36K | 21,710 |
| Barry Ticho CHIEF MEDICAL OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −1,600 | $31.06 | $49.70K | 20,110 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Aug 18, 2026 | Sale | −2,716 | $32.01 | $86.94K | 21,370 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Aug 18, 2026 | Sale | −145 | $32.47 | $4.71K | 21,225 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 18, 2026 | Sale | −4,525 | $32.01 | $144.85K | 25,897 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 18, 2026 | Sale | −242 | $32.47 | $7.86K | 25,655 |
| Edward M. Kaye MD Director | Aug 18, 2026 | Sale | −11,930 | $32.01 | $381.88K | 125,194 |
| Edward M. Kaye MD Director | Aug 18, 2026 | Sale | −637 | $32.47 | $20.68K | 124,557 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Aug 14, 2026 | Option exercise | +6,000 | – | – | 24,086 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 14, 2026 | Option exercise | +10,000 | – | – | 30,422 |
| Edward M. Kaye MD Director | Aug 14, 2026 | Option exercise | +26,250 | – | – | 137,124 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 3, 2026 | Sale(10b5-1 plan) | −1,269 | $29.45 | $37.37K | 20,422 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 3, 2026 | Sale(10b5-1 plan) | −5,907 | $28.95 | $171.01K | 21,691 |
| Barry Ticho CHIEF MEDICAL OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −6,728 | $32.62 | $219.47K | 28,098 |
| Barry Ticho CHIEF MEDICAL OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −500 | $33.27 | $16.64K | 27,598 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Jun 16, 2026 | Sale(10b5-1 plan) | −1,457 | $29.95 | $43.64K | 18,086 |
| Barry Ticho CHIEF MEDICAL OFFICER | Jun 1, 2026 | Sale(10b5-1 plan) | −1,795 | $30.58 | $54.89K | 34,826 |
| Barry Ticho CHIEF MEDICAL OFFICER | May 1, 2026 | Sale(10b5-1 plan) | −2,243 | $32.79 | $73.55K | 36,621 |
| Barry Ticho CHIEF MEDICAL OFFICER | Apr 1, 2026 | Sale(10b5-1 plan) | −1,838 | $32.66 | $60.03K | 38,864 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 20, 2026 | Sale(10b5-1 plan) | −601 | $34.41 | $20.68K | 19,543 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 20, 2026 | Sale(10b5-1 plan) | −8,692 | $33.64 | $292.40K | 20,144 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 19, 2026 | Option exercise | +1,365 | $2.19 | $2.99K | 42,163 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 19, 2026 | Sale(10b5-1 plan) | −1,461 | $29.99 | $43.82K | 40,702 |
| Thomas Leggett Chief Financial Officer | Mar 18, 2026 | Sale | −2,173 | $31.28 | $67.97K | 10,381 |
| Thomas Leggett Chief Financial Officer | Mar 18, 2026 | Sale | −172 | $31.79 | $5.47K | 10,209 |
| Thomas Leggett Chief Financial Officer | Mar 18, 2026 | Sale | −37 | $32.85 | $1.22K | 10,172 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 18, 2026 | Sale | −334 | $31.79 | $10.62K | 28,908 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 18, 2026 | Sale | −72 | $32.85 | $2.37K | 28,836 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 18, 2026 | Sale | −4,222 | $31.28 | $132.06K | 29,242 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 18, 2026 | Sale(10b5-1 plan) | −483 | $31.79 | $15.35K | 40,901 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 18, 2026 | Sale(10b5-1 plan) | −103 | $32.85 | $3.38K | 40,798 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 18, 2026 | Sale(10b5-1 plan) | −6,100 | $31.28 | $190.81K | 41,384 |
| Jason Hoitt Chief Patient Officer | Mar 18, 2026 | Sale | −30 | $32.85 | $986 | 10,276 |
| Jason Hoitt Chief Patient Officer | Mar 18, 2026 | Sale | −1,762 | $31.28 | $55.12K | 10,445 |
| Jason Hoitt Chief Patient Officer | Mar 18, 2026 | Sale | −139 | $31.79 | $4.42K | 10,306 |
| Thomas Leggett Chief Financial Officer | Mar 17, 2026 | Sale | −1,274 | $32.74 | $41.71K | 13,476 |
| Thomas Leggett Chief Financial Officer | Mar 17, 2026 | Sale | −922 | $33.38 | $30.78K | 12,554 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 17, 2026 | Sale | −1,791 | $33.38 | $59.78K | 33,464 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 17, 2026 | Sale | −2,476 | $32.74 | $81.06K | 35,255 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 17, 2026 | Sale(10b5-1 plan) | −2,587 | $33.38 | $86.35K | 47,484 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 17, 2026 | Sale(10b5-1 plan) | −3,577 | $32.74 | $117.11K | 50,071 |
| Jason Hoitt Chief Patient Officer | Mar 17, 2026 | Sale | −1,033 | $32.74 | $33.82K | 12,955 |
| Jason Hoitt Chief Patient Officer | Mar 17, 2026 | Sale | −748 | $33.38 | $24.97K | 12,207 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 15, 2026 | Option exercise | +7,475 | – | – | 19,731 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 15, 2026 | Option exercise | +12,000 | – | – | 37,731 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 15, 2026 | Option exercise | +6,000 | – | – | 25,731 |
| Edward M. Kaye MD Director | Mar 15, 2026 | Option exercise | +26,250 | – | – | 110,874 |
| Edward M. Kaye MD Director | Mar 15, 2026 | Option exercise | +35,500 | – | – | 84,624 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 15, 2026 | Option exercise | +10,000 | – | – | 42,898 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 15, 2026 | Option exercise | +13,100 | – | – | 32,898 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 15, 2026 | Option exercise | +10,750 | – | – | 53,648 |
| Thomas Leggett Chief Financial Officer | Mar 15, 2026 | Option exercise | +14,750 | – | – | 14,750 |
| Jason Hoitt Chief Patient Officer | Mar 15, 2026 | Option exercise | +10,000 | – | – | 13,988 |
| Arthur A. Levin Director | Mar 13, 2026 | Sale(10b5-1 plan) | −605 | $36.80 | $22.26K | 4,237 |
| Adrian R. Krainer Director | Mar 10, 2026 | Sale(10b5-1 plan) | −33,243 | $39.74 | $1.32M | 283,302 |
| Arthur Tzianabos Interim Executive Chair, Director | Mar 10, 2026 | Option exercise | +3,955 | $8.33 | $32.95K | 35,694 |
| Arthur Tzianabos Interim Executive Chair, Director | Mar 10, 2026 | Sale(10b5-1 plan) | −4,355 | $40.00 | $174.20K | 31,339 |
| Adrian R. Krainer Director | Mar 2, 2026 | Sale(10b5-1 plan) | −7,229 | $39.66 | $286.70K | 316,545 |
| Arthur A. Levin Director | Dec 31, 2025 | Option exercise | +1,211 | – | – | 4,842 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Dec 8, 2025 | Sale(10b5-1 plan) | −1,300 | $31.60 | $41.08K | 14,509 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| D. Allan Jonathan Officer | Oct 2, 2026 | 627 | $16.31K | Oct 2, 2026 | Restricted Stock Units |
| Ticho Baruch Officer | Aug 3, 2026 | 20,967 | $605.11K | Aug 3, 2026 | Restricted Stock Units |
| S. Ticho Baruch Officer | Jul 1, 2026 | 7,228 | $236.50K | Jul 1, 2026 | Restricted Stock Units |
| D. Allan Jonathan Officer | Jun 16, 2026 | 1,457 | $43.71K | Jun 16, 2026 | Restricted Stock Units |
| S. Ticho Baruch Officer | May 1, 2026 | 4,038 | $132.12K | May 1, 2026 | Restricted Stock Units |
| S. Ticho Baruch Officer | Apr 1, 2026 | 1,838 | $59.85K | Apr 1, 2026 | Restricted Stock Units |
| Allan Jonathan Officer | Mar 20, 2026 | 9,293 | $308.43K | Mar 20, 2026 | Restricted Stock Units |
| S. Ticho Baruch Officer | Mar 19, 2026 | 1,461 | $45.32K | Mar 19, 2026 | Exercise of Stock Options |
| A. Levin Arthur Director | Mar 13, 2026 | 605 | $22.07K | Mar 13, 2026 | Restricted Stock Units |
| Tzianabos Arthur Director | Mar 10, 2026 | 90,508 | $3.47M | Mar 10, 2026 | Exercise of Stock Options |
| Krainer Adrian Director | Mar 2, 2026 | 40,472 | $1.47M | Mar 2, 2026 | Founders Shares |
| M. Kaye Edward Director | Dec 8, 2025 | 13,430 | $414.58K | Dec 8, 2025 | Performance Stock Units |
| Allan Jonathan Officer | Dec 8, 2025 | 3,978 | $122.80K | Dec 8, 2025 | Performance Stock Units |
| Allan Jonathan Officer | Dec 5, 2025 | 7,781 | $241.60K | Dec 5, 2025 | Restricted Stock Units |
| Ticho Baruch Officer | Dec 5, 2025 | 1,989 | $61.76K | Dec 5, 2025 | Restricted Stock Units |